Michelle R Roberts1, Gabrielle M Baker2, Yujing J Heng2, Michael E Pyle2, Kristina Astone3, Bernard A Rosner4, Laura C Collins2, A Heather Eliassen5, Rulla M Tamimi6. 1. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: robertsmichellerene@gmail.com. 2. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. 3. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 5. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Abstract
BACKGROUND: Pathologist and computational assessments have been used to evaluate immunohistochemistry (IHC) in epidemiologic studies. We compared Definiens Tissue Studio® to pathologist scores for 17 markers measured in breast tumor tissue microarrays (TMAs) [AR, CD20, CD4, CD8, CD163, EPRS, ER, FASN, H3K27, IGF1R, IR, Ki67, phospho-mTOR, PR, PTEN, RXR, and VDR]. METHODS: 5 914 Nurses' Health Study participants, diagnosed 1976-2006 (NHS) and 1989-2006 (NHS-II), were included. IHC was conducted by the Dana-Farber/Harvard Cancer Center Specialized Histopathology Laboratory. The percent of cells staining positive was assessed by breast pathologists. Definiens output was used to calculate a weighted average of percent of cells staining positive across TMA cores for each marker. Correlations between pathologist and computational scores were evaluated with Spearman correlation coefficients. Receiver-operator characteristic curves were constructed, using pathologist scores as comparison. RESULTS: Spearman correlations between pathologist and Definiens assessments ranged from weak (RXR, rho=-0.05; CD163, rho = 0.10) to strong (Ki67, rho = 0.79; pmTOR, rho = 0.77). The area under the curve was >0.70 for all markers except RXR. CONCLUSION: Our data indicate that computational assessments exhibit variable correlations with interpretations made by an expert pathologist, depending on the marker evaluated. This study provides evidence supporting the use of computational platforms for IHC evaluation in large-scale epidemiologic studies, with the caveat that pilot studies are necessary to investigate agreement with expert assessments. In sum, computational platforms may provide greater efficiency and facilitate high-throughput epidemiologic analyses.
BACKGROUND: Pathologist and computational assessments have been used to evaluate immunohistochemistry (IHC) in epidemiologic studies. We compared Definiens Tissue Studio® to pathologist scores for 17 markers measured in breast tumor tissue microarrays (TMAs) [AR, CD20, CD4, CD8, CD163, EPRS, ER, FASN, H3K27, IGF1R, IR, Ki67, phospho-mTOR, PR, PTEN, RXR, and VDR]. METHODS: 5 914 Nurses' Health Study participants, diagnosed 1976-2006 (NHS) and 1989-2006 (NHS-II), were included. IHC was conducted by the Dana-Farber/Harvard Cancer Center Specialized Histopathology Laboratory. The percent of cells staining positive was assessed by breast pathologists. Definiens output was used to calculate a weighted average of percent of cells staining positive across TMA cores for each marker. Correlations between pathologist and computational scores were evaluated with Spearman correlation coefficients. Receiver-operator characteristic curves were constructed, using pathologist scores as comparison. RESULTS: Spearman correlations between pathologist and Definiens assessments ranged from weak (RXR, rho=-0.05; CD163, rho = 0.10) to strong (Ki67, rho = 0.79; pmTOR, rho = 0.77). The area under the curve was >0.70 for all markers except RXR. CONCLUSION: Our data indicate that computational assessments exhibit variable correlations with interpretations made by an expert pathologist, depending on the marker evaluated. This study provides evidence supporting the use of computational platforms for IHC evaluation in large-scale epidemiologic studies, with the caveat that pilot studies are necessary to investigate agreement with expert assessments. In sum, computational platforms may provide greater efficiency and facilitate high-throughput epidemiologic analyses.
Authors: Kelly L Bolton; Montserrat Garcia-Closas; Ruth M Pfeiffer; Máire A Duggan; William J Howat; Stephen M Hewitt; Xiaohong R Yang; Robert Cornelison; Sarah L Anzick; Paul Meltzer; Sean Davis; Petra Lenz; Jonine D Figueroa; Paul D P Pharoah; Mark E Sherman Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Z M A Mohammed; D C McMillan; B Elsberger; J J Going; C Orange; E Mallon; J C Doughty; J Edwards Journal: Br J Cancer Date: 2012-01-03 Impact factor: 7.640
Authors: Elton Rexhepaj; Donal J Brennan; Peter Holloway; Elaine W Kay; Amanda H McCann; Goran Landberg; Michael J Duffy; Karin Jirstrom; William M Gallagher Journal: Breast Cancer Res Date: 2008-10-23 Impact factor: 6.466
Authors: William J Howat; Fiona M Blows; Elena Provenzano; Mark N Brook; Lorna Morris; Patrycja Gazinska; Nicola Johnson; Leigh-Anne McDuffus; Jodi Miller; Elinor J Sawyer; Sarah Pinder; Carolien H M van Deurzen; Louise Jones; Reijo Sironen; Daniel Visscher; Carlos Caldas; Frances Daley; Penny Coulson; Annegien Broeks; Joyce Sanders; Jelle Wesseling; Heli Nevanlinna; Rainer Fagerholm; Carl Blomqvist; Päivi Heikkilä; H Raza Ali; Sarah-Jane Dawson; Jonine Figueroa; Jolanta Lissowska; Louise Brinton; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Angela Cox; Ian W Brock; Simon S Cross; Malcolm W Reed; Fergus J Couch; Janet E Olson; Peter Devillee; Wilma E Mesker; Caroline M Seyaneve; Antoinette Hollestelle; Javier Benitez; Jose Ignacio Arias Perez; Primitiva Menéndez; Manjeet K Bolla; Douglas F Easton; Marjanka K Schmidt; Paul D Pharoah; Mark E Sherman; Montserrat García-Closas Journal: J Pathol Clin Res Date: 2014-12-04
Authors: Mustapha Abubakar; William J Howat; Frances Daley; Lila Zabaglo; Leigh-Anne McDuffus; Fiona Blows; Penny Coulson; H Raza Ali; Javier Benitez; Roger Milne; Herman Brenner; Christa Stegmaier; Arto Mannermaa; Jenny Chang-Claude; Anja Rudolph; Peter Sinn; Fergus J Couch; Rob A E M Tollenaar; Peter Devilee; Jonine Figueroa; Mark E Sherman; Jolanta Lissowska; Stephen Hewitt; Diana Eccles; Maartje J Hooning; Antoinette Hollestelle; John Wm Martens; Carolien Hm van Deurzen; Manjeet K Bolla; Qin Wang; Michael Jones; Minouk Schoemaker; Annegien Broeks; Flora E van Leeuwen; Laura Van't Veer; Anthony J Swerdlow; Nick Orr; Mitch Dowsett; Douglas Easton; Marjanka K Schmidt; Paul D Pharoah; Montserrat Garcia-Closas Journal: J Pathol Clin Res Date: 2016-04-06
Authors: Rulla M Tamimi; A Heather Eliassen; Tengteng Wang; Yujing J Heng; Gabrielle M Baker; Vanessa C Bret-Mounet; Liza M Quintana; Lisa Frueh; Susan E Hankinson; Michelle D Holmes; Wendy Y Chen; Walter C Willett; Bernard Rosner Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-10-04 Impact factor: 4.090